Clinical trials recruiting in Guanzhou, China

Phase breakdown

Conditions recruiting in Guanzhou, China

Recruiting trials in Guanzhou, China

• A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
  NCT07367529 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
  NCT06951503 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• ASPIrin in Reducing Events in Dialysis ( ASPIRED )
  NCT04381143 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
  NCT05536505 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
  NCT06265350 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
  NCT06575322 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
  NCT05997719 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
  NCT06079983 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
  NCT05800340 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
  NCT06492421 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
  NCT03778814 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
  NCT03755739 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Guanzhou, China?

12 recruiting trials have at least one study site in Guanzhou, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.